key: cord-0972021-yhdghck7 authors: Lavik, Andrew R; Ebekozien, Osagie; Noor, Nudrat; Alonso, G Todd; Polsky, Sarit; Blackman, Scott M; Chen, Justin; Corathers, Sarah D; Demeterco-Berggren, Carla; Gallagher, Mary Pat; Greenfield, Margaret; Garrity, Ashley; Rompicherla, Saketh; Rapaport, Robert; Yayah Jones, Nana-Hawa title: Trends in type 1 diabetic ketoacidosis during COVID-19 surges at seven US centers: highest burden on non-Hispanic Blacks date: 2022-04-05 journal: J Clin Endocrinol Metab DOI: 10.1210/clinem/dgac158 sha: 657554ceac513817e232d9eb7d717ac232914853 doc_id: 972021 cord_uid: yhdghck7 OBJECTIVE: We examined United States (US) trends in diabetic ketoacidosis (DKA) among individuals with type 1 diabetes (T1D) during the COVID-19 pandemic at seven large US medical centers and factors associated with these trends. METHODS: We compared DKA events among children and adults with T1D during COVID-19 surge 1 (March-May 2020) and COVID-19 surge 2 (August-October 2020) to the same periods in 2019. Analysis was performed using descriptive statistics and Chi-square tests. RESULTS: We found no difference in the absolute number of T1D patients experiencing DKA in 2019 vs 2020. However, a higher proportion of non-Hispanic Blacks (NHB) experienced DKA in 2019 than non-Hispanic Whites (NHW) (44.6% vs 16.0%; p<0.001), and this disparity persisted during the COVID-19 pandemic (48.6% vs 18.6%; p<0.001). DKA was less common among patients on continuous glucose monitor (CGM) or insulin pump in 2020 compared to 2019 (CGM: 13.2% vs 15.0%, p<0.001; insulin pump: 8.0% vs 10.6%, p<0.001). In contrast to annual DKA totals, a higher proportion of patients had DKA during COVID-19 surges 1 and 2 compared to the same months in 2019 (surge 1: 7.1% vs 5.4%, p<0.001; surge 2: 6.6% vs 5.7%, p=0.001). CONCLUSIONS: DKA frequency increased among T1D patients during COVID-19 surges with highest frequency among NHB. DKA was less common among patients using CGM or insulin pumps. These findings highlight the urgent need for improved strategies to prevent DKA among patients with T1D—not only under pandemic conditions, but under all conditions—especially among populations most affected by health inequities. A c c e p t e d M a n u s c r i p t The COVID-19 pandemic has had a far-reaching impact on 21 st century health care. For type 1 diabetes (T1D), multiple reports indicate that presentations of newly diagnosed T1D have been more severe during the COVID-19 pandemic than in previous years (1) (2) (3) (4) (5) (6) (7) (8) (9) . The current pandemic has also exposed inequities present in our health care system (10) (11) (12) (13) (14) . Among individuals with T1D and concomitant COVID-19 infection, patients from minority races/ethnicities have been more likely to present to hospitals with diabetic ketoacidosis (DKA), a common, life-threatening, yet generally preventable diabetes complication that results from insulin deficiency and is characterized by production of excess acids in the form of ketones (15) (16) (17) . Despite the disruptive effect of COVID-19 on health care delivery and the risks such disruptions pose to those with T1D, studies assessing trends in DKA during the COVID-19 pandemic and the populations most likely to be affected have been limited, with conflicting results (2, 5, (18) (19) (20) . Within the above context, the T1D Exchange Quality Improvement Collaborative (T1DX-QI) developed a multicenter population health study to examine trends in DKA across the United States (US) and across the lifespan during the COVID-19 pandemic relative to a prepandemic comparison. T1DX-QI is a growing community with clinics across the US engaged in sharing data and best practices to improve diabetes health care delivery and outcomes (21) . Our aim was to understand the factors associated with observed trends in DKA during the pandemic to drive clinical quality improvement activities during the pandemic and thereafter. This retrospective cohort study was conducted by T1DX-QI and was comprised of aggregate A c c e p t e d M a n u s c r i p t Participating institutions shared de-identified aggregate data by month through existing data use agreements using the Smartsheet online data platform (www.smartsheet.com). Descriptive statistics were used to summarize data. Categorical data were presented with frequency and percentage of patients in each group. Bar graphs and line charts were used to visualize categorical data and trends over time. Midpoint coding method was used to calculate mean and standard deviation from categorical age data. Chi-square tests were used to compare differences in patient characteristics during the pandemic period compared to the pre-pandemic comparison group. Loess smoothing was performed to visualize DKA trends across years. All analysis was performed using R version 2.4.1. Seven large medical centers located across the US contributed to this study. Together, the total T1D population from these centers was 15,267 in 2019 and 15,176 in 2020 (Table 1) . There were no year-to-year differences in the total number of patients with DKA or withinrace differences in DKA by race/ethnicity (Table 1 and Figure 1 ). There were also no differences in the proportion of patients with DKA by gender (Table 1) , insurance type, or severity of DKA (not shown). However, the proportion of patients with a DKA event was higher in 2020 among patients aged >/=60 years (32.2% vs 29.4%, p=0.02) and among patients with Hemoglobin A1c (HbA1c) <7% (19.1% vs 16.4%, p=0.008; Table 1 ). Conversely, the proportion of patients with a DKA event was lower in 2020 among patients A c c e p t e d M a n u s c r i p t using a CGM (13.2% vs 15.0%, p<0.001; Table 1 and Figure 2 ) or an insulin pump (8.0% vs 10.6%, p<0.001; Table 1 and Figure 2 ). The early COVID-19 pandemic in the US consisted of an initial rise in COVID-19 cases in the spring of 2020 and a second rise in mid-to-late summer 2020 (22). Corresponding to these national trends, we observed an increased proportion of new COVID-19 case submissions to the T1DX-QI registry during spring and late summer 2020 and therefore Table 2 and Figure 1b ). There were no differences in DKA events by age or gender during COVID-19 surges 1 or 2 compared to the same periods in 2019, nor were there within-race differences in DKA ( Table 2) . As with year-to-year trends, the proportion of patients with a DKA event was lower among individuals using insulin pumps during both COVID-19 surges compared to the same periods in 2019 (surge 1: 6.4% vs 10.3%, p=0.008; surge 2: 8.1% vs 11.2%, p=0.03) (Table 2b) . Of A c c e p t e d M a n u s c r i p t (n=10,570) were NHW, 6.3% (n=959) were NHB, 9.5% (n=1,447) were Hispanic, 0.9% were Asian (n=135), 7.8% (n=1,186) were listed as -Other,‖ and 5.6% (n=850) had no race/ethnicity reported. These percentages are consistent with national data of race/ethnicity among individuals with T1D (23) . Month-to-month DKA frequencies were higher among NHB patients with T1D compared to NHW (p<0.001) or Hispanics (p=0.01) in both 2019 and 2020 ( Figure 3 ). There were no within-race differences in monthly DKA frequencies in 2019 vs 2020. Moreover, a higher proportion of NHB patients experienced DKA in 2019 compared to NHW or Hispanics (44.6% among NHB vs 16.0% among NHW (p<0.001) and 17.2% among Hispanics (p=0.001)) and this disparity persisted in 2020 during the COVID-19 pandemic (48.6% among NHB vs 18.4% among NHW (p<0.001) and 13.7% among Hispanics (p=0.001)). We report here the results of a large US study examining trends in DKA in a diverse cohort of children and adults with T1D during the first year of the COVID-19 pandemic. We found that the proportion of patients with a DKA event was higher during both COVID-19 surge 1 (March-May 2020) and surge 2 (August-October 2020) compared to the same periods in the year prior. Compared to other racial/ethnic groups, the proportion of patients with DKA was highest by far among NHB prior to the pandemic and during both COVID-19 surges. Conversely, DKA was less common for individuals using CGMs and insulin pumps during the COVID-19 pandemic compared to the year prior. These findings underscore the critical need for innovative efforts not only to prevent DKA in patients with T1D under pandemic conditions but to do so especially for those most affected by health inequities. To our knowledge, this is the largest study to date to report on trends in DKA in the US during the COVID-19 pandemic. Comprised of month-by-month DKA admission data from seven large medical institutions located around the US and corresponding to over 15,000 A c c e p t e d M a n u s c r i p t children and adults with T1D, our observation that DKA frequencies were higher during COVID-19 surges 1 and 2 compared to the same periods in the year prior illustrates the disruptive nature of the COVID-19 pandemic on individuals with T1D as the virus swept through the US (Figure 1A and 1B) . Many investigations into the effect COVID-19 has on T1D care have focused on the pandemic's impact on incidence and severity of newly diagnosed diabetes (1) (2) (3) (4) (5) (6) (7) (8) (9) . However, the current study includes not only individuals with newly diagnosed T1D but also the much larger population with established T1D ( Figure 1B) . Among other reports that included patients with established T1D, a study of 11 Israeli emergency departments found that DKA rates increased among pediatric patients with established T1D from March-May 2020 compared to the same period in 2019 (18) . Similarly, a study of six pediatric diabetes centers in Saudi Arabia including children aged 1-14 years with newly diagnosed or established T1D found an increase in overall DKA frequency from March-May 2020, though no difference in DKA frequency among patients with established T1D (2). In the US, a study of five emergency departments in New York City reported a rise in DKA diagnosis from March-May 2020, but a distinction between newly diagnosed vs established T1D among patients was not made (19) . In contrast, a cross-sectional study involving 53 Italian pediatric diabetes centers found no difference in DKA among children with established T1D in the first 40 days of the COVID-19 pandemic compared to the same period in the previous year, though this finding was limited by small sample size (5) . Also, a population-based study using a national dataset from England found that emergency hospital admissions with diagnosis code DKA regardless of diabetes type were higher from March 1 to June 30, 2020 and from Nov 1, 2020 to Feb 28, 2021 compared to equivalent periods in 2017-20, but lower specifically for individuals with established T1D (20) . The current study is distinct from these prior reports given its large and geographically diverse US patient population, the inclusion of both children and adults with T1D, the requirement for laboratory-confirmed diagnosis of DKA, and its longitudinal nature, which allowed the impact of two distinct US COVID-19 surges on individuals with T1D to be characterized. Of note, multiple studies have also investigated DKA frequency among T1D patients infected with A c c e p t e d M a n u s c r i p t COVID-19 (16, (24) (25) (26) (27) (28) . This study was not designed to evaluate this question, and COVID- were collected where available. In our study, twenty-three patients diagnosed with DKA tested positive for COVID-19 in COVID-19 surge 1, and six patients with DKA tested positive for COVID-19 in COVID-19 surge 2 (Table 2B) . A concerning finding of this study is that DKA was most common by far among NHB with T1D during both COVID-19 surges (Figure 3 ). The finding that health disparities exist in T1D between racial/ethnic groups is consistent with a growing body of literature (23, (29) (30) (31) (32) (33) (34) . As the pandemic spread, racial inequities relating to COVID-19 were identified and widely reported, including among individuals with T1D and COVID-19 (12) (13) (14) (15) 26) . However, despite this heightened awareness of racial health inequities during COVID-19 and efforts made to address them, we observed that DKA frequency did not improve among NHB as the pandemic progressed (Figure 3 ). These findings underscore the critical need to redouble efforts to target the root causes of health disparities in T1D, both during the COVID-19 pandemic and beyond. To this end, the T1DX-QI has recently provided a framework to facilitate equitable post-COVID-19 diabetes care (35) . We observed that Hispanics did not suffer from the same inequity in DKA frequency as NHB. Our findings are similar to those of Ebekozien and colleagues, who found NHB patients with T1D had increased odds of presenting with DKA with COVID-19 infection compared to Hispanic patients (15) . These findings are similar to inequities in T1D outcomes before the COVID-19 pandemic, with Hispanic patients faring better than NHB patients (23) . There are several potential explanations for this difference, including the role of the Hispanic culture, which is significantly different from that of NHB patients, as described by LaVeist-Ramos and colleagues (36) . Furthermore, the contributors to inequities for Hispanic T1D patients are different from those of NHB as both groups are not homogenous (37) . A c c e p t e d M a n u s c r i p t Another key finding of this study is that the proportion of patients with a DKA event was lower among individuals on CGMs or insulin pumps during the COVID-19 pandemic compared to the year prior (Figure 2A and 2B) . It is well known that CGM and insulin pump use improves management of T1D and is associated with decreased rates of acute T1D complications (38) (39) (40) . However, the unique observation here is that CGM and insulin pump use were each associated with lower frequency of DKA in 2020 during the COVID-19 pandemic compared to the year prior. This finding suggests that CGM and insulin pump use may help protect individuals with T1D from DKA in the midst of the COVID-19 pandemic, perhaps by increasing automation of diabetes care such that disruptions in care resulting in DKA are less frequent. Our study did not adjust for the impact of diabetes technology use and other potential confounders on DKA frequency. However, an earlier manuscript from our group using a different dataset demonstrated that CGM, insulin pump, and combined CGM and insulin pump use is associated with reduced risk of DKA and hospitalization during COVID-19 infection (41) . Likewise, rates of hospitalization are higher among pediatric and adult patients with both T1D and COVID-19 who do not use CGM or insulin pumps compared to those who use these devices (16, 26) . Despite the benefits of CGM and insulin pump use during COVID-19, differential access to diabetes technologies remains a major and growing health disparity in T1D care today (23, 41, 42) . Rates of diabetes technology use are lowest by far among NHB, in part due to social inequities and systemic racism (41, 42) . Due to the aggregate nature by which data was collected for the current study, the demographic associations of diabetes technology users and non-users cannot be determined. However, it is revealing in this dataset that CGM and insulin pump use were each associated with decreased frequency of DKA during the COVID-19 pandemic, while NHB, who historically have the lowest rates of diabetes technology use, had the highest frequency of DKA. While this study has several strengths, we also acknowledge several limitations. Though data from seven centers from across the US were included in this study, these may not be A c c e p t e d M a n u s c r i p t representative of all diabetes centers across the US which limits the generalizability of findings. Further, it is unlikely that all patients with DKA presented to their home diabetes centers for care; therefore, additional DKA events likely occurred that were not included in the totals presented in this study. Also, as this was a large multicenter analysis, data were submitted in monthly aggregates, and not patient level data, which restricted the analyses we were able to perform. Due to the manner by which aggregate data was collected, we were restricted in separating patient level characteristics of patients presenting in DKA at T1D diagnosis from those with established T1D presenting in DKA. As a result, we could assess month-to-month trends in DKA among patients with established T1D but not individual factors of these patients. Further, since data were collected from electronic medical records of seven independent hospital systems, there was inherently some variation as to how data elements were tracked and tabulated at each institution. In summary, this study identified that DKA was more frequent among patients with T1D during COVID-19 surges 1 and 2 compared to the same periods in the year prior. Moreover, DKA frequency was highest by far among NHB, both during the COVID-19 pandemic and prior. More encouragingly, we provide evidence that DKA was less common among patients on CGM or insulin pump during the first year of the COVID-19 pandemic. Further work is needed to improve strategies to prevent DKA in patients with T1D under pandemic conditions as well as post-pandemic, especially among those most impacted by inequities in health care. Some or all datasets generated during and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request. M a n u s c r i p t Diabetic ketoacidosis at type 1 diabetes diagnosis in children during the COVID-19 pandemic The Impact of COVID-19 Pandemic Lockdown on the Incidence of New-Onset Type 1 Diabetes and Ketoacidosis Among Saudi Children Increased frequency of severe diabetic ketoacidosis at type 1 diabetes onset among children during COVID-19 pandemic lockdown: an observational cohort study Increased paediatric presentations of severe diabetic ketoacidosis in an Australian tertiary centre during the COVID-19 pandemic Delayed the Diagnosis and Worsened the Presentation of Type 1 Diabetes in Children? Diabetes Care Diabetes During the COVID-19 Pandemic in Germany Presentation of newly diagnosed type 1 diabetes in children and young people during COVID-19: a national UK survey New-Onset Type 1 Diabetes in Children During COVID-19: Multicenter Regional Findings in the U.K. Diabetes Care Increased Prevalence of Diabetic Ketoacidosis Among Colorado Children at Diagnosis of Type 1 Diabetes During the COVID-19 Pandemic Lockdown Resolves After Reopening Covid-19, equity, and inclusiveness Breaking Links in the Chain of Racial Disparities for COVID-19 Patient and Hospital Factors Associated With Differences in Mortality Rates Among Black and White US Medicare Beneficiaries Hospitalized With COVID-19 Infection The COVID-19 pandemic and health inequalities Avoiding a legacy of unequal non-communicable disease burden after the COVID-19 pandemic. The Lancet Diabetes & Endocrinology Inequities in Diabetic Ketoacidosis Among Patients With Type 1 Diabetes and COVID-19: Data From 52 US Clinical Centers Diabetic ketoacidosis drives COVID-19 related hospitalizations in children with type 1 diabetes Diabetic ketoacidosis and the hyperglycemic hyperosmolar state Diabetic Ketoacidosis at Emergency Department Presentation During the First Months of the SARS-CoV-2 Pandemic in Israel: A Multicenter Cross-Sectional Study SARS-CoV-2 Infection and Associated Rates of Diabetic Ketoacidosis in a New York City Emergency Department Temporal trends in emergency admissions for diabetic ketoacidosis in people with diabetes in England before and during the COVID-19 pandemic: a population-based study Establishment of the T1D Exchange Quality Improvement Collaborative (T1DX-QI) Inequities in Health Outcomes in Children and Adults With Type 1 Diabetes: Data From the T1D Exchange Quality Improvement Collaborative Type 1 Diabetes and COVID-19: Preliminary Findings From a Multicenter Surveillance Study in the U.S. Diabetes Care Increased DKA at presentation among newly diagnosed type 1 diabetes patients with or without COVID-19: Data from a multi-site surveillance registry COVID-19 Hospitalization in Adults with Type 1 Diabetes: Results from the T1D Exchange Multicenter Surveillance Study Characteristics of and Mortality Associated With Diabetic Ketoacidosis Among US Patients Hospitalized With or Without COVID-19 Intensive Care Unit Admission, Mechanical Ventilation, and Mortality Among Patients With Type 1 Diabetes Hospitalized for COVID-19 in the U.S. Diabetes Care Association of Race and Ethnicity With Glycemic Control and Hemoglobin A1c Levels in Youth With Type 1 Diabetes Racial/Ethnic Minority Youth With Recent-Onset Type 1 Diabetes Have Poor Prognostic Factors Glycemic Control in Youth with Diabetes: The SEARCH for Diabetes in Youth Study Racial-Ethnic Disparities in Management and Outcomes Among Children With Type 1 Diabetes Racial and Socioeconomic Disparities in Pediatric Type 1 Diabetes: Time for a Paradigm Shift in Approach. Diabetes Care Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry Equitable Post-COVID-19 Care: A Practical Framework to Integrate Health Equity in Diabetes Management Are black Hispanics black or Hispanic? Exploring disparities at the intersection of race and ethnicity Hispanic Caregivers' experience of pediatric type 1 diabetes: A qualitative study Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes Association of Insulin Pump Therapy vs Insulin Injection Therapy With Severe Hypoglycemia, Ketoacidosis, and Glycemic Control Among Children, Adolescents, and Young Adults With Type 1 Diabetes Diabetes Technology Use for Management of Type 1 Diabetes Is Associated With Fewer Adverse COVID-19 Outcomes: Findings From the T1D Exchange COVID-19 Surveillance Registry A Decade of Disparities in Diabetes Technology Use and HbA1c in Pediatric Type 1 Diabetes: A Transatlantic Comparison A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t